New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
13:37 EDTPFEEarnings Preview: Pfizer near 52-week high ahead of Q4 results
Pfizer (PFE) is scheduled to report Q4 earnings before the market open on Tuesday January 29, with a conference call scheduled for 10:00 am ET. Pfizer is a biopharmaceutical company that engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide... EXPECTATIONS: Analysts are looking for EPS of 44c on revenue of $14.4B, according to First Call. The consensus range for EPS is 43c-47c on revenue of $13.94B-$14.66B... LAST QUARTER: Pfizer reported Q3 EPS of 53c against estimates of 53c on revenue of $14B against estimates of $14.64B. At the time of its Q3 earnings release, the drug giant gave FY12 EPS guidance $2.14-$2.17 on a consensus of $2.21. Note that consensus estimates for FY12 have since been reduced to $2.16... STREET RESEARCH: On December 31, Leerink Swann said it believes Bristol-Myers (BMY) and Pfizer's (PFE) Eliquis was approved with a solid label and is positioned to be the leader for stroke prevention in atrial fibrillation... PRICE ACTION: Pfizer shares are trading close to a 52-week high of $27.30, which was reached on January 24. Shares are up about 8% in the month of January. In early afternoon trading, Pfizer shares are near flat at ~$27.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
12:06 EDTPFEPfizer receives orphan status for lung cancer drug
The FDA granted Pfizer orphan status for its treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations, dacomitinib.
08:37 EDTPFEPfizer says EC approves expanded indication for Prevenar 13
Pfizer announced that the European Commission approved an expanded indication for the use of Prevenar 13 -- pneumococcal polysaccharide conjugate vaccine 13-valent, adsorbed -- for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults, which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia, including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease in adults aged 65 and older.
March 2, 2015
16:31 EDTPFEPfizer files automatic mixed securities shelf
Subscribe for More Information
09:02 EDTPFEAstraZeneca mulls linking bonuses to Pfizer defense pledges, Sunday Times says
Subscribe for More Information
February 26, 2015
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
February 24, 2015
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
February 20, 2015
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
07:23 EDTPFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use